Craton Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-07-2024
- Paid Up Capital ₹ 0.10 M
as on 15-07-2024
- Company Age 6 Year, 27 Days
- Last Filing with ROC 31 Mar 2021
- Revenue 6973.67%
(FY 2020)
- Profit -1203.33%
(FY 2020)
- Ebitda 5729.65%
(FY 2020)
- Net Worth -28.94%
(FY 2020)
- Total Assets 145.01%
(FY 2020)
About Craton Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Gaurav Pandya, Nishith Pathak, and Arpitaben Patel serve as directors at the Company.
- CIN/LLPIN
U24239GJ2018PTC105361
- Company No.
105361
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2018
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Craton Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gaurav Pandya  | Director | 20-Nov-2021 | Current |
| Nishith Pathak | Director | 20-Nov-2021 | Current |
| Arpitaben Patel | Director | 20-Nov-2021 | Current |
Financial Performance of Craton Pharmaceuticals.
Craton Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 6973.67% increase. The company also saw a substantial fall in profitability, with a 1203.33% decrease in profit. The company's net worth observed a substantial decline by a decrease of 28.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Craton Pharmaceuticals?
In 2019, Craton Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bhc Pharmaceutical Private LimitedActive 1 year 9 monthsGaurav Pandya and Nishith Pathak are mutual person
- Bhc Services Private LimitedActive 2 years 7 months
Gaurav Pandya and Nishith Pathak are mutual person
- Sarthi Educare Private LimitedActive 2 years 9 months
Gaurav Pandya and Nishith Pathak are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Craton Pharmaceuticals?
Unlock and access historical data on people associated with Craton Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Craton Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Craton Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
